Lin Mei, Zhang Xiao-Long, You Rui, Yang Qi, Zou Xiong, Yu Kai, Liu You-Ping, Zou Ru-Hai, Hua Yi-Jun, Huang Pei-Yu, Wang Jin, Zhao Qi, Jiang Xiao-Bing, Tang Jun, Gu Yang-Kui, Yu Tao, He Gui-Ping, Xie Yu-Long, Wang Zhi-Qiang, Liu Ting, Chen Si-Yuan, Zuo Zhi-Xiang, Chen Ming-Yuan
Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, P. R. China.
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine.
Theranostics. 2021 Apr 19;11(13):6427-6444. doi: 10.7150/thno.53229. eCollection 2021.
Reportedly, nasopharyngeal carcinoma (NPC) patients with MHC I Class aberration are prone to poor survival outcomes, which indicates that the deficiency of tumor neoantigens might represent a mechanism of immune surveillance escape in NPC. To clearly delineate the landscape of neoantigens in NPC, we performed DNA and RNA sequencing on paired primary tumor, regional lymph node metastasis and distant metastasis samples from 26 patients. Neoantigens were predicted using pVACseq pipeline. Subtype prediction model was built using random forest algorithm. Portraying the landscape of neoantigens in NPC for the first time, we found that the neoantigen load of NPC was above average compared to that of other cancers in The Cancer Genome Atlas program. While the quantity and quality of neoantigens were similar among primary tumor, regional lymph node metastasis and distant metastasis samples, neoantigen depletion was more severe in metastatic sites than in primary tumors. Upon tracking the clonality change of neoantigens, we found that neoantigen reduction occurred during metastasis. Building a subtype prediction model based on reported data, we observed that subtype I lacked T cells and suffered from severe neoantigen depletion, subtype II highly expressed immune checkpoint molecules and suffered from the least neoantigen depletion, and subtype III was heterogenous. These results indicate that neoantigens are conducive to the guidance of clinical treatment, and personalized therapeutic vaccines for NPC deserve deeper basic and clinical investigations to make them feasible in the future.
据报道,主要组织相容性复合体I类(MHC I)出现异常的鼻咽癌(NPC)患者生存结局往往较差,这表明肿瘤新抗原的缺乏可能是NPC免疫逃逸监视的一种机制。为了清晰描绘NPC中新抗原的全貌,我们对26例患者的配对原发性肿瘤、区域淋巴结转移灶和远处转移灶样本进行了DNA和RNA测序。使用pVACseq流程预测新抗原。采用随机森林算法构建亚型预测模型。我们首次描绘了NPC中新抗原的全貌,发现与癌症基因组图谱计划中的其他癌症相比,NPC的新抗原负荷高于平均水平。虽然原发性肿瘤、区域淋巴结转移灶和远处转移灶样本中新抗原的数量和质量相似,但转移部位的新抗原耗竭比原发性肿瘤更严重。在追踪新抗原的克隆性变化时,我们发现在转移过程中会出现新抗原减少。基于已报道的数据构建亚型预测模型,我们观察到I型缺乏T细胞且新抗原耗竭严重,II型高表达免疫检查点分子且新抗原耗竭最少,III型则具有异质性。这些结果表明,新抗原有助于指导临床治疗,NPC的个性化治疗性疫苗值得进行更深入的基础和临床研究,以便未来使其可行。